Literature DB >> 11096736

Alzheimer's Disease.

.   

Abstract

Use of valid diagnostic criteria is extremely important in the recognition of Alzheimer's disease (AD). Patients with mild to moderate Alzheimer's disease should be started on a cholinesterase inhibitor and possibly anti-inflammatory agents, antioxidants (vitamin E or selegiline), and estrogen replacement therapy (for postmenopausal women). Close follow-up of functioning is needed to be able to provide symptomatic relief and possibly slow down the progression of the disease. Comorbid medical conditions as well as superimposed psychiatric disturbances should be aggressively treated. Pharmacologic interventions and environmental engineering (including support for family members) should be used throughout the course of the disease. Genetic testing is not recommended in asymptomatic family members considering the enormous potential for job and insurance discrimination.

Entities:  

Year:  2000        PMID: 11096736     DOI: 10.1007/s11940-000-0023-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  47 in total

1.  NSAIDs and incident Alzheimer's disease. The Rotterdam Study.

Authors:  B A in 't Veld; L J Launer; A W Hoes; A Ott; A Hofman; M M Breteler; B H Stricker
Journal:  Neurobiol Aging       Date:  1998 Nov-Dec       Impact factor: 4.673

2.  Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type.

Authors:  P N Tariot; B Goldstein; C A Podgorski; C Cox; N Frambes
Journal:  Am J Geriatr Psychiatry       Date:  1998       Impact factor: 4.105

3.  An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations.

Authors:  B G Pollock; B H Mulsant; R Sweet; L D Burgio; M A Kirshner; K Shuster; J Rosen
Journal:  Am J Geriatr Psychiatry       Date:  1997       Impact factor: 4.105

4.  Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

Authors:  R E Becker; J A Colliver; S J Markwell; P L Moriearty; L K Unni; S Vicari
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-03       Impact factor: 2.703

Review 5.  Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.

Authors:  E Y Shintani; K M Uchida
Journal:  Am J Health Syst Pharm       Date:  1997-12-15       Impact factor: 2.637

6.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 7.  Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease.

Authors:  M A Raskind
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

8.  Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.

Authors:  L S Schneider; M R Farlow; V W Henderson; J M Pogoda
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

9.  Safety of tacrine: clinical trials, treatment IND, and postmarketing experience.

Authors:  S I Gracon; M J Knapp; W G Berghoff; M Pierce; R DeJong; S J Lobbestael; J Symons; S L Dombey; F A Luscombe; D Kraemer
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-06       Impact factor: 2.703

10.  Behavioral effects of trazodone in Alzheimer's disease.

Authors:  F Lebert; F Pasquier; H Petit
Journal:  J Clin Psychiatry       Date:  1994-12       Impact factor: 4.384

View more
  3 in total

1.  Alzheimer's disease.

Authors:  A S Schachter; K L Davis
Journal:  Dialogues Clin Neurosci       Date:  2000-06       Impact factor: 5.986

Review 2.  Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach.

Authors:  Eleonora Del Prete; Maria Francesca Beatino; Nicole Campese; Linda Giampietri; Gabriele Siciliano; Roberto Ceravolo; Filippo Baldacci
Journal:  J Pers Med       Date:  2020-11-11

Review 3.  Current Biomedical Use of Copper Chelation Therapy.

Authors:  Silvia Baldari; Giuliana Di Rocco; Gabriele Toietta
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.